Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $1.3 million.

  • 4D Molecular Therapeutics' Depreciation & Amortization (CF) rose 596.64% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 182.44%. This contributed to the annual value of $4.7 million for FY2024, which is 1068.03% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Depreciation & Amortization (CF) of $1.3 million as of Q3 2025, which was up 596.64% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q3 2025 and a low of $370000.0 during Q2 2021
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.0 million (2023), whereas its average is $855842.1.
  • In the last 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) skyrocketed by 16000.0% in 2022 and then plummeted by 1040.07% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $390000.0 in 2021, then surged by 160.0% to $1.0 million in 2022, then rose by 8.68% to $1.1 million in 2023, then fell by 0.54% to $1.1 million in 2024, then rose by 15.05% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.2 million for Q2 2025, and $1.1 million during Q1 2025.